Gene: KRAS ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs112445441
rs112445441
KRAS
T 0.700 CausalMutation CLINVAR Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. 18794081

2008
dbSNP: rs112445441
rs112445441
KRAS
G 0.700 CausalMutation CLINVAR Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. 18794081

2008
dbSNP: rs112445441
rs112445441
KRAS
T 0.700 CausalMutation CLINVAR KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 15696205

2005
dbSNP: rs112445441
rs112445441
KRAS
G 0.700 CausalMutation CLINVAR BRAF and RAS mutations in human lung cancer and melanoma. 12460918

2002
dbSNP: rs112445441
rs112445441
KRAS
T 0.700 CausalMutation CLINVAR BRAF and RAS mutations in human lung cancer and melanoma. 12460918

2002
dbSNP: rs121913238
rs121913238
KRAS
T 0.700 CausalMutation CLINVAR Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. 19047918

2009
dbSNP: rs121913238
rs121913238
KRAS
T 0.700 CausalMutation CLINVAR Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. 18794081

2008
dbSNP: rs121913238
rs121913238
KRAS
T 0.700 CausalMutation CLINVAR BRAF and RAS mutations in human lung cancer and melanoma. 12460918

2002
dbSNP: rs121913240
rs121913240
KRAS
C 0.700 CausalMutation CLINVAR BRAF and RAS mutations in human lung cancer and melanoma. 12460918

2002
dbSNP: rs121913240
rs121913240
KRAS
C 0.700 CausalMutation CLINVAR Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. 18794081

2008
dbSNP: rs121913240
rs121913240
KRAS
A 0.700 CausalMutation CLINVAR BRAF and RAS mutations in human lung cancer and melanoma. 12460918

2002
dbSNP: rs121913240
rs121913240
KRAS
A 0.700 CausalMutation CLINVAR Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. 17062680

2006
dbSNP: rs121913240
rs121913240
KRAS
A 0.700 CausalMutation CLINVAR KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 15696205

2005
dbSNP: rs121913240
rs121913240
KRAS
A 0.700 CausalMutation CLINVAR Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. 18794081

2008
dbSNP: rs121913529
rs121913529
KRAS
0.790 GeneticVariation BEFREE Using genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria. 23959381

2013
dbSNP: rs121913529
rs121913529
KRAS
A 0.790 CausalMutation CLINVAR KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways. 21169357

2011
dbSNP: rs121913529
rs121913529
KRAS
0.790 GeneticVariation BEFREE A biopsy acquired after disease progression revealed the original SDC4-ROS1 fusion along with a KRAS point mutation (p.G12D).We reviewed the related literature to determine the frequency of gene mutations in non-small cell lung cancer patients. 28971587

2018
dbSNP: rs121913529
rs121913529
KRAS
0.790 GeneticVariation BEFREE Two different mutations were found in 14 NSCLCs and the most frequent one was G12D and G12V (n = 8). 30368666

2019
dbSNP: rs121913529
rs121913529
KRAS
G 0.790 CausalMutation CLINVAR KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 15696205

2005
dbSNP: rs121913529
rs121913529
KRAS
A 0.790 CausalMutation CLINVAR KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 15696205

2005
dbSNP: rs121913529
rs121913529
KRAS
A 0.790 GeneticVariation CLINVAR A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. 20609353

2010
dbSNP: rs121913529
rs121913529
KRAS
T 0.790 CausalMutation CLINVAR BRAF and RAS mutations in human lung cancer and melanoma. 12460918

2002
dbSNP: rs121913529
rs121913529
KRAS
0.790 GeneticVariation BEFREE NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation. 22247021

2012
dbSNP: rs121913529
rs121913529
KRAS
T 0.790 CausalMutation CLINVAR Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 17332249

2007
dbSNP: rs121913529
rs121913529
KRAS
0.790 GeneticVariation BEFREE The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma. 30335711

2018